专利检索 ap:("DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION" OR "IMMUNOFORGE CO.,LTD.") AND inv:"Doohyun Lee" 第 1 页

1.

发明公开
3-((8-((1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER 审中-公开

公开(公告)号：US20230295153A1

公开(公告)日：2023-09-21

申请号：US17801757

申请日：2021-02-26

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION , IMMUNOFORGE CO.,LTD.

发明人： Doohyun Lee , Seungyeon Lee , Ye Ri Han , Chun Young Im , So Young Kim , Nam Hui Kim , Hwan Geun Choi , Eunhwa Ko , Heegyum Moon , Sun Joo Lee , Sang Bum Kim , Hyo-Ji Kim , Sion Lee , Sung-Min Ahn , Kiho Chang , Eunkyu Lee , Hyun Jin Kwon , Myeong-Sook Jeong , Ji Young Kim

IPC分类号： C07D471/04 , A61P35/00

CPC分类号： C07D471/04 , A61P35/00

摘要： The present invention relates to a 3-((8-((1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-phenylbenzamide derivative, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating cancer. The derivative can significantly inhibit the proliferation of cancer cells by inhibiting kinases, particularly Bcr-Abl kinase or Bcr-Abl (T315I) kinase. Therefore, the derivative can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.

2.

发明申请
COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT 有权

公开(公告)号：US20230010508A1

公开(公告)日：2023-01-12

申请号：US17773325

申请日：2020-10-29

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION

发明人： Ji-Hoon Yu , Chun Young lm , SoYoung Kim , Ye Ri Han , Doohyun Lee , Hui-Jeon Jeon , Sang-Hyun Min , Bae Jun Oh , Sang-Wook Park , Dong-Kyu Choi , Young-Kyu Kim , Sung Hwan Kim , Yuri Lee , Seungyeon Lee , Nam Hui Kim , Sang Bum Kim , Ju-Sik Min

IPC分类号： A61K47/55 , A61P35/00 , A61K47/54

摘要： The present invention relates to a compound comprising an EZH2 inhibitor and an E3 ligase binder, and a pharmaceutical composition for preventing or treating EZH2-associated disease and a pharmaceutical composition for selective protein degradation containing the same as an active ingredient. Since the compound of the present invention can selectively degrade EZH2, it can be effectively used for the treatment of EZH2-related diseases and cancers, particularly, cancers in which EZH2 is overexpressed, and can be usefully used for the selective degradation of EZH2.